Therefore, it is necessary to consolidate clinical studies and global data analysis to improve our current view of the role of TNKS1/2 in the origin of the alterations that lead to tumor development and the use of new therapeutic agents based on inhibition by tankyrases. The gene discussed is TNKS; the disease is neoplasm.